Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Seeking Broad Intervention In India, Eli Lilly Goes To Roots To Check Non-communicable Diseases

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Following the Indian government's heightened concerns over a sharply increased prevalence rate of non-communicable diseases such as diabetes and cancer, Eli Lilly & Co. has allocated $8-9 million to analyze the disease burden in India and devise intervention strategies based on the data

You may also be interested in...



As India’s Diabetes Market Grows, Eli Lilly Brings In A New Leader

With an eye on diabetes and non-communicable diseases, Lilly taps new leadership in India.

Big Pharma To Invest More On NCD Partnerships Over Next Decade – IFPMA Report

Although Big Pharma is investing more in partnerships related to non-communicable diseases such as cancer and diabetes, gaps remain in tech transfer activities and local solutions in developing nations where NCDs are on the rise.

GSK Sees Enduring Pricing Pressure Unlikely, Novo Projects Lower Growth In China, Lilly Bolsters Diabetes Presence In India: Emerging Markets Round Up (Part 1)

In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets. In Q3, earnings in emerging markets were slightly down for GlaxoSmithKline PLC, Novo Nordisk A/S, and Eli Lilly & Co, mostly due to increased pricing pressure as well as increased competition in the diabetes market, with local players rapidly gaining market share..

Related Content

Latest News
UsernamePublicRestriction

Register

SC079022

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel